Yazaki T, Takamiya Y, Costello P C, Mineta T, Menon A G, Rabkin S D, Martuza R L
Georgetown Brain Tumor Center, Georgetown University Medical Center, Washington, DC 20007, USA.
J Neurooncol. 1995;23(1):23-9. doi: 10.1007/BF01058456.
Meningiomas are relatively common (22%) vascular brain tumors. 3-11% of meningiomas are malignant, and defy currently available therapy. Inhibition of neovascularization is one potential strategy for treating these hypervascular tumors. Inhibition of tumor-induced angiogenesis by TNP-470 (previously termed AGM-1470), a synthetic analogue of fumagillin, was tested on the growth of human non-malignant and malignant meningiomas in nude mice. TNP-470 significantly inhibited tumor neovascularization and tumor growth of both non-malignant and malignant meningiomas. TNP-470 is now in human trial and should be tested for efficacy in treating malignant or recurrent aggressive meningiomas.
脑膜瘤是相对常见（占22%）的脑血管瘤。3% - 11%的脑膜瘤是恶性的，且对目前可用的治疗方法无效。抑制新血管形成是治疗这些高血管性肿瘤的一种潜在策略。通过烟曲霉素的合成类似物TNP - 470（以前称为AGM - 1470）抑制肿瘤诱导的血管生成，已在裸鼠体内对人非恶性和恶性脑膜瘤的生长进行了测试。TNP - 470显著抑制了非恶性和恶性脑膜瘤的肿瘤新血管形成及肿瘤生长。TNP - 470目前正在进行人体试验，应该对其治疗恶性或复发性侵袭性脑膜瘤的疗效进行测试。
